BRIEF-U.S. FDA extends review period for Baricitinib, an investigational rheumatoid arthritis treatment
January 13, 2017 at 16:56 PM EST
* U.S. FDA extends review period for baricitinib, an investigational rheumatoid arthritis treatment
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.